Effects of LGM2605 on a primate model of asthma
The invention provides compositions and methods for treating asthma in a subject in need thereof comprising administering chemically synthesized secoisolaricirecinol diglucoside (SDG), and in particular, a racemic mixture of the SDG (LGM2605), stereoisomers thereof, metabolites thereof, and analogs thereof. Also provided are methods for treating or preventing ozone-induced damage in a subject in need thereof.
1. A method for treating ozone-induced damage in a biomolecule, a cell, or a tissue of a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of chemically synthesized SDG, wherein the biomolecule, the cell, or the tissue is located in a respiratory airway of the subject.
2. The method of claim 1 , wherein the chemically synthesized SDG comprises a racemic mixture of the SDG.
3. The method of claim 1 , wherein administration of the chemically synthesized SDG alleviates or eliminates respiratory airway hyperactivity in the subject.
4. The method of claim 3 , wherein the respiratory airway is an upper respiratory airway, a lower respiratory airway or a combination thereof.
5. The method of claim 1 , wherein administration of the chemically synthesized SDG alleviates or eliminates BAL inflammation in the subject.
6. The method of claim 5 , wherein alleviation or elimination of the BAL inflammation comprises reducing ozone-induced BAL neutrophilia.
7. The method of claim 1 , wherein administration of the chemically synthesized SDG alleviates or eliminates oxidative stress.
8. The method of claim 1 , wherein the chemically synthesized SDG inhibits surfactant protein-D (SP-D) de-oligomerization.
9. The method of claim 1 , wherein the chemically synthesized SDG protects the biomolecule, the cell, or the tissue from ozone-induced IL-6, IL-25, IL-33, and CCL11 gene expression in respiratory airway epithelial cells.
10. The method of claim 1 , wherein the chemically synthesized SDG reduces BAL group 2 innate lymphoid cells (ILC2) and CD1c+mDC dendritic cells in the respiratory airway of the subject.
11. The method of claim 1 , wherein the subject is one who will be exposed to ozone.
12. The method of claim 1 , wherein the subject is one who has been exposed to ozone.
13. The method of claim 1 , wherein the subject is a human subject.
14. The method of claim 1 , wherein the chemically synthesized SDG is administered in a dietary composition.
15. The method of claim 1 , wherein the chemically synthesized SDG is administered orally.
16. A method for protecting a biomolecule, a cell, or a tissue from ozone-induced damage in a subject in need thereof, the method comprising: administering to the subject therapeutically effective amount of at least one bioactive ingredient, wherein the bioactive ingredient comprises a therapeutically effective amount of chemically synthesized SDG.
17. The method of claim 16 , wherein the chemically synthesized SDG comprises a racemic mixture of the SDG.
18. The method of claim 16 , wherein the biomolecule is a nucleic acid.
19. The method of claim 16 , wherein the biomolecule is a protein or a lipid.
20. The method of claim 16 , wherein the chemically synthesized SDG is an SDG analog.
21. The method of claim 16 , wherein the chemically synthesized SDG is administered in a dietary composition.
22. The method of claim 16 , wherein said step of administering comprises orally administering.
23. The method of claim 16 , wherein the chemically synthesized SDG is in a concentration about 1 nanomolar (nM) to about 1 molar (M).
24. The method of claim 23 , wherein the SDG concentration is about 25 μM to about 250 μM.
25. The method of claim 16 , wherein the subject is a human subject.